Luciano Foggia
Naples, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Baricitinib versus ritlecitinib for severe alopecia areata: A 24-week real-world study.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: April 11, 2026
Persistence of biologics and Janus kinase inhibitors in atopic dermatitis: preliminary 24-month analysis.
Journal: Clinical and experimental dermatology
Published: December 13, 2025
Comparative clinical, trichoscopic and safety outcomes of baricitinib, ritlecitinib and upadacitinib in alopecia areata: a real-world experience.
Journal: Clinical and experimental dermatology
Published: September 20, 2025
Atypical forms of pityriasis versicolor: Case series and literature review.
Journal: JAAD case reports
Published: September 11, 2025
Biologics targeting IL-23 in moderate-to-severe psoriasis: lessons learned from real-world use.
Journal: Expert opinion on biological therapy
Published: June 16, 2025
Letter: Atopic Dermatitis, 2-HEMA Allergic Contact Dermatitis, and Chemical Leukoderma: Which Relationship?
Journal: Dermatitis : contact, atopic, occupational, drug
Published: April 29, 2025
Effectiveness and safety of baricitinib in severe alopecia areata: 48-week results.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: February 28, 2025
Reply to: Upadacitinib for the management of overlapping psoriasis and atopic dermatitis: a case series.
Journal: International journal of dermatology
Published: October 19, 2024
Comment on 'Efficacy and tolerance of dupilumab in patients with moderate-to-severe atopic dermatitis and obesity' by Dupuis et al.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: October 16, 2024
Efficacy of Janus kinase inhibitors in the treatment of psoriasiform atopic dermatitis.
Journal: Clinical and experimental dermatology
Published: April 12, 2024
Comparison of Long-Term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis Between Dupilumab-Exposed and Dupilumab-Naïve Patients.
Journal: Clinical drug investigation
Published: December 06, 2023
Showing 1-11 of 11
Last Updated: 09/26/2026